Unweighted sample | Weighted sample | |||
---|---|---|---|---|
HR (95%CI) | P-value | HR (95%CI) | P-value | |
Presence of FT at baseline | ||||
Time to death | 0.41 (0.22–0.80) | 0.006* | 0.62 (0.31–1.22) | 0.166 |
Time to UPDRS-III 11-point increase | 0.77 (0.43–1.30) | 0.339 | 0.98 (0.54–1.76) | 0.934 |
Time to conversion to H&Y stage ≥3 | 0.98 (0.50–1.78) | 0.938 | 0.66 (0.33–1.30) | 0.224 |
Time to dyskinesia | 0.41 (0.14–0.95) | 0.061 | 0.44 (0.17–1.17) | 0.101 |
Time to MoCA 3-point decrease | 0.93 (0.51–1.61) | 0.793 | 0.67 (0.36–1.23) | 0.198 |
FT as initial symptom | ||||
Time to death | 2.82 (1.55–5.11) | < 0.001* | 1.75 (0.55–5.54) | 0.342 |
Time to UPDRS-III 11-point increase | 0.97 (0.60–1.55) | 0.889 | 0.74 (0.24–2.31) | 0.606 |
Time to conversion to H&Y stage ≥3 | 1.24 (0.69–2.12) | 0.467 | 0.34 (0.08–1.56) | 0.167 |
Time to dyskinesia | 0.51 (0.21–1.27) | 0.149 | 0.81 (0.18–3.70) | 0.790 |
Time to MoCA 3-point decrease | 1.04 (0.63–1.72) | 0.885 | 0.45 (0.13–1.63) | 0.226 |